Q4 25 EPS
$2.08
MISS 4.70%
Est. $2.18
Q4 25 Revenue
$60.16B
BEAT +1.26%
Est. $59.41B
vs S&P Since Q4 25
+52.5%
BEATING MARKET
CAH +68.6% vs S&P +16.0%
Full Year 2025 Results
FY 25 EPS
$8.24
MISS 12.65%
Est. $9.43
FY 25 Revenue
$222.58B
MISS 0.33%
Est. $223.30B
Market Reaction
Did CAH Beat Earnings? Q4 2025 Results
Cardinal Health posted a mixed but largely encouraging fourth quarter for fiscal year 2025, beating Wall Street's earnings expectations while falling modestly short on the top line. The healthcare distribution giant reported non-GAAP diluted EPS of $… Read more Cardinal Health posted a mixed but largely encouraging fourth quarter for fiscal year 2025, beating Wall Street's earnings expectations while falling modestly short on the top line. The healthcare distribution giant reported non-GAAP diluted EPS of $2.08, edging past the $2.03 consensus estimate by 2.46%, as non-GAAP operating earnings climbed 19% year-over-year to $719.00 million. Revenue of $60.16 billion grew 0.8% from a year ago but came in 1.19% below the $60.89 billion consensus, a shortfall the company had largely telegraphed given the previously communicated expiration of the OptumRx contract; strip out that headwind, and underlying revenue surged 21%. The standout driver was broad segment momentum, with all five operating units delivering double-digit profit growth, led by a 49% jump in GMPD segment profit to $70.00 million. Looking ahead, Cardinal Health raised its fiscal 2026 non-GAAP EPS guidance to $9.30 to $9.50, a $0.20 increase from its prior outlook, and announced the $1.90 billion acquisition of urology MSO Solaris Health, extending its specialty platform to roughly 3,000 providers across 32 states.
Key Takeaways
- • Brand and specialty pharmaceutical sales growth from existing and new customers
- • MSO platform acquisitions driving Pharmaceutical and Specialty Solutions segment profit
- • Volume growth from existing customers in GMPD segment
- • Advanced Diabetes Supply acquisition contributing to Other segment growth
- • Lower share count from share repurchases supporting EPS growth
- • All five operating segments growing profit at double-digit rates in FY2025
CAH YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
CAH Revenue by Segment
With YoY comparisons, source: SEC Filings
“Fiscal 2025 was a transformative year for Cardinal Health, and we closed the year with momentum, delivering strong fourth quarter results. The broad-based operational strength, with all five of our operating segments growing profit double-digits, reflects the disciplined execution of our strategy and our investments for growth. We enter Fiscal 2026 with confidence, evidenced by our increased financial outlook, as we continue to evolve towards reaching our full potential.”
— Jason Hollar, Q4 2025 Earnings Press Release
CAH Earnings Trends
CAH vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CAH EPS Trend
Earnings per share: estimate vs actual
CAH Revenue Trend
Quarterly revenue: estimate vs actual
CAH Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q3 26 BEAT | $2.79 | $3.17 | +13.70% | $60.94B | -2.19% |
| Q2 26 BEAT | $2.37 | $2.63 | +11.17% | $65.63B | +0.60% |
| Q1 26 BEAT | $2.17 | $2.55 | +17.33% | $64.01B | +8.00% |
| Q4 25 MISS FY | $2.18 | $2.08 | -4.70% | $60.16B | +1.26% |
| FY Full Year | $9.43 | $8.24 | -12.65% | $222.58B | -0.33% |
| Q3 25 BEAT | $2.15 | $2.35 | +9.36% | $54.88B | -0.78% |